A Phase 3 interventional study of insulin degludec/liraglutide and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 143 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-27.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 6 that started in 2016, is one of 49 in phase 3, and was the 44th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,012 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 37th largest by enrollment of the 428 interventional ones that give a count, is one of 20 that started in 2016, is one of 187 in phase 3, and was the 400th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Africa, Asia, Europe, North America and South America. The purpose is to compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve subjects with type 2 diabetes mellitus inadequately controlled with oral anti diabetics.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 1,012 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/liraglutide
Drug: insulin glargine
Drug pages: Insulin degludec · Liraglutide
Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification
Inadequate glycaemic control and need for treatment intensification was defined as a glycosylated haemoglobin (HbA1c) of 7.0% or greater at 2 consecutive visits from week 26, including week 26 if HbA1c was greater than or equal to 7% at week 12. Time from randomisation to inadequate glycaemic control and need for treatment intensification was analysed using a stratified log-rank test where treatment, baseline HbA1c group and previous OAD treatment were included as strata in the model. The variable "baseline HbA1c group" was a dichotomised baseline HbA1c variable with 2 categories: HbA1c \< 8.5% or HbA1c ≥ 8.5% and the variable "previous OAD treatment" was a categorical variable with 2 categories: SU ± OAD(s) (SU users) or OAD(s) (Non-SU users). 25%, median (50%) and 75% percentiles for the cumulative distribution function were obtained from the Kaplan-Meier survival function.
Time frame: Weeks 0-104 + 7 days follow-up-1 + 30 days follow-up-2
Time From Randomisation to HbA1c >6.5% at 2 Consecutive Visits
Time to HbA1c \> 6.5% at 2 consecutive visits is defined as time from randomization to HbA1c \> 6.5% at 2 consecutive planned scheduled visits from week 26 (including week 26 if HbA1c was \> 6.5% at week 12). Time from randomisation to HbA1c \>6.5% at 2 consecutive visits was analysed using a stratified log-rank test where treatment, baseline HbA1c group and previous OAD treatment were included as strata in the model. The variable "baseline HbA1c group" was a dichotomised baseline HbA1c variable with 2 categories: HbA1c \< 8.5% or HbA1c ≥ 8.5% and the variable "previous OAD treatment" was a categorical variable with 2 categories: SU ± OAD(s) (SU users) or OAD(s) (Non-SU users). 25%, median (50%) and 75% percentiles for the cumulative distribution function were obtained from the Kaplan-Meier survival function.
Time frame: Weeks 0-104 + 7 days follow-up-1 + 30 days follow-up-2
Change in HbA1c
Change in HbA1c from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Body Weight
Change in body weight from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Insulin Dose
Insulin dose after 26 and 104 weeks of treatment is presented.
Time frame: Week 26, week 104
Participants Who Achieved (Yes/no): HbA1c <7.0%
Percentage of participants who achieved (yes/no) HbA1c \<7.0% at week 26 and week 104 is presented.
Time frame: Week 26, week 104
Participants Who Achieved (Yes/no): HbA1c <7.0% Without Weight Gain
Percentage of participants who achieved (yes/no) HbA1c \<7.0% without weight gain at week 26 and week 104 is presented.
Time frame: Week 26, week 104
Participants Who Achieved (Yes/no): HbA1c <7.0% Without Treatment-emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes
Severe or BG confirmed symptomatic hypoglycaemia was defined as an episode that was severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Percentage of participants who achieved (yes/no) HbA1c \<7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes at week 26 and week 104 is presented.
Time frame: Week 26, week 104
Participants Who Achieved (Yes/no): HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes and Without Weight Gain
Severe or BG confirmed symptomatic hypoglycaemia was defined as an episode that was severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Percentage of participants who achieved (yes/no) HbA1c \<7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes and without weight gain at week 26 and week 104 is presented.
Time frame: Week 26, week 104
Participants Who Achieved (Yes/no): HbA1c ≤6.5%
Percentage of participants who achieved (yes/no) HbA1c ≤6.5% at week 26 and week 104 is presented.
Time frame: Week 26, week 104
Participants Who Achieved (Yes/no): HbA1c ≤6.5% Without Weight Gain
Percentage of participants who achieved (yes/no) HbA1c ≤6.5% without weight gain at week 26 and week 104 is presented.
Time frame: Week 26, week 104
Participants Who Achieved (Yes/no): HbA1c ≤6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Severe or BG confirmed symptomatic hypoglycaemia is defined as an episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Percentage of participants who achieved (yes/no) HbA1c ≤6.5% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes at week 26 and week 104 is presented.
Time frame: Week 26, week 104
Participants Who Achieved (Yes/no): HbA1c ≤6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes and Without Weight Gain
Severe or BG confirmed symptomatic hypoglycaemia is defined as an episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Percentage of participants who achieved (yes/no) HbA1c ≤6.5% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes and without weight gain at week 26 and week 104 is presented.
Time frame: Week 26, week 104
Change in FPG
Change in fasting plasma glucose (FPG) from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
SMPG-9-point Profile (Individual Points in the Profile)
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. Self-measured plasma glucose (SMPG)-9-point profile (individual points in the profile) at week 26 and week 104 is presented.
Time frame: Week 26, week 104
Change in SMPG-mean 9-point Profile
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. Change in SMPG-mean 9-point profile from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in SMPG-mean Postprandial Increment Over All Meals
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. Change in SMPG-mean postprandial increment over all meals from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Blood Pressure (Systolic and Diastolic)
Change in blood pressure (systolic and diastolic) from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Fasting C-peptide
Change in fasting C-peptide (measured in nanomoles per liter \[nmol/L\]) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
Time frame: Week 0, week 26, week 104
Change in Fasting Human Insulin
Change in fasting human insulin (measured in picomoles per liter \[pmol/L\]) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
Time frame: Week 0, week 26, week 104
Change in Fasting Total Cholesterol
Change in fasting total cholesterol (measured in mmol/L) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
Time frame: Week 0, week 26, week 104
Change in Fasting LDL-cholesterol
Change in fasting low density lipoprotein (LDL)-cholesterol (measured in mmol/L) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
Time frame: Week 0, week 26, week 104
Change in Fasting HDL-cholesterol
Change in fasting high density lipoprotein (HDL)- cholesterol (measured in mmol/L) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
Time frame: Week 0, week 26, week 104
Change in Fasting VLDL-cholesterol
Change in fasting very low density lipoprotein (VLDL)-cholesterol (measured in mmol/L) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
Time frame: Week 0, week 26, week 104
Change in Fasting Triglycerides
Change in fasting triglycerides (measured as mmol/L) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
Time frame: Week 0, week 26, week 104
Change in Fasting Free Fatty Acids
Change in fasting free fatty acids (measured as mmol/L) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
Time frame: Week 0, week 26, week 104
Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks of Treatment
Severe or BG confirmed symptomatic hypoglycaemia is defined as an episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during 26 weeks of treatment is presented.
Time frame: Weeks 0-26
Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 104 Weeks of Treatment
Severe or BG confirmed symptomatic hypoglycaemia is defined as an episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during 104 weeks of treatment is presented.
Time frame: Weeks 0-104
Number of Treatment Emergent Hypoglycaemic Episodes During 26 Weeks of Treatment
Hypoglycaemic episodes (SMPG value ≤3.9 mmol/L (70 mg/dL)) were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent hypoglycaemic episodes according to ADA during 26 weeks of treatment is presented.
Time frame: Weeks 0-26
Number of Treatment Emergent Hypoglycaemic Episodes During 104 Weeks of Treatment
Hypoglycaemic episodes (SMPG value ≤3.9 mmol/L (70 mg/dL)) were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment emergent hypoglycaemic episodes according to ADA during 104 weeks of treatment is presented.
Time frame: Weeks 0-104
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks of Treatment
Severe or BG confirmed symptomatic hypoglycaemia is defined as an episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 both inclusive. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes during 26 weeks of treatment is presented.
Time frame: Weeks 0-26
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 104 Weeks of Treatment
Severe or BG confirmed symptomatic hypoglycaemia is defined as an episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 both inclusive. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes during 104 weeks of treatment is presented.
Time frame: Weeks 0-104
Number of TEAEs During 26 Weeks of Treatment
An adverse event is any untoward medical occurrence in a participant administered a product, and which does not necessarily have a causal relationship with this treatment. A treatment emergent adverse event (TEAE) was defined as an adverse event that had onset date on or after the first day of exposure to trial product and no later than 7 days after the last day of trial product. If the event had onset date before the first day of exposure on trial product and increased in severity during the treatment period and until 7 days after the last drug date, then this event was also considered as a TEAE. Number of TEAEs during 26 weeks of treatment is presented.
Time frame: Weeks 0-26
Number of TEAEs During 104 Weeks of Treatment
An adverse event is any untoward medical occurrence in a participant administered a product, and which does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event that had onset date on or after the first day of exposure to trial product and no later than 7 days after the last day of trial product. If the event had onset date before the first day of exposure on trial product and increased in severity during the treatment period and until 7 days after the last drug date, then this event was also considered as a TEAE. Number of TEAEs during 104 weeks of treatment is presented.
Time frame: Week 0 to week 104
Eye Examination Category
Fundus photography or a dilated fundoscopy was performed at baseline (within 12 weeks prior to week 0) and week 104. The investigator interpreted each eye's (left and right) results and categorised them as: normal, abnormal not clinically significant (NCS) or abnormal clinically significant (CS). Number of participants in each category at baseline and week 104 were presented.
Time frame: Baseline (within 12 weeks prior to week 0), week 104
ECG Evaluation
The electrocardiogram (ECG) was assessed at baseline (within 2 weeks prior to week 0) and week 104. The investigator interpreted the results and categorised them as: normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 104 are presented.
Time frame: Baseline (within 2 weeks prior to week 0), week 104
Change in Urine Albumin/Creatinine Ratio
Change in urine albumin/creatinine ratio from baseline (week 0) to week 104 is presented.
Time frame: Week 0, week 104
Change in Pulse Rate
Change in pulse rate from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Biochemistry Parameter- Creatinine, Total Bilirubin
Change in biochemistry parameter- creatinine, total bilirubin from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Biochemistry Parameter- Albumin
Change in biochemistry parameter- albumin from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Biochemistry Parameters- ALP, ALT, AST, Lipase and Amylase
Change in biochemistry parameters- alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lipase and amylase from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Biochemistry Parameter- Sodium, Potassium and Calcium
Change in sodium, potassium and calcium from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Haematological Parameter- Haemoglobin
Change in haemoglobin from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Haematological Parameter- Haematocrit
Change in haematocrit from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Haematological Parameter- Erythrocytes
Change in erythrocytes from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Haematological Parameter- Thrombocytes and Leukocytes
Change in thrombocytes and leukocytes from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Haematological Parameter- Eosinophils
Change in eosinophils from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Haematological Parameter- Neutrophils
Change in neutrophils from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Haematological Parameter- Basophils
Change in basophils from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Haematological Parameter- Monocytes
Change in monocytes from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Haematological Parameter- Lymphocytes
Change in lymphocytes from baseline (week 0) to week 26 and week 104 is presented.
Time frame: Week 0, week 26, week 104
Change in Calcitonin
The number of participants who reported low, normal and high levels of calcitonin in relation to reference ranges at baseline (week 0), week 26 and week 104 are presented.
Time frame: Week 0, week 26, week 104
Change in Short Form Health Survey Version 2.0 (SF-36v2™, Acute Version) Health Survey: Scores From the 8 Domains and Summaries of the Physical Component Score (PCS) and the Mental Component Score (MCS)
SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ (acute version) questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary (PCS) and mental component summary (MCS)). The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in the sub-domain scores and component summary (PCS and MCS) scores are presented. A positive change score indicates an improvement since baseline.
Time frame: Week 0, week 26, week 104
Change in TRIM-D
Treatment related impact measures-diabetes (TRIM-D) was developed according to the FDA guidance from 2009 on development of new PRO measures. The questionnaire consists of 5 sub-domains, which are scored according to a 1-5 point scale with a higher score indicating a better health state (less negative impact). Sub-domain scores are calculated by summing across items in the same sub-domain, and the total score is calculated by summing scores from all the sub-domains. The highest possible summed score within a sub-domain ranges from 20 (compliance sub-domain) to 40 (psychological health sub-domain) points and the highest possible total score is 140 points. Change in TRIM-D total score from baseline (week 0) to week 26 and week 104 is presented. A positive change score indicates an improvement since baseline.
Time frame: Week 0, week 26, week 104
The trial was conducted at 130 sites in Argentina (4),Czech Republic (4), Hungary (5), India (11), Israel (8), Italy (7), Mexico (4), Norway (7), Poland (3), Russian Federation (8), Slovakia (5), South Africa (10), Turkey (8), United Kingdom (9) and United States (37).
| Milestone | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Started | 506 | 506 |
| Exposed | 506 | 504 |
| Completed | 484 | 481 |
| Not completed | 22 | 25 |
| Withdrew: Adverse event | 2 | 6 |
| Withdrew: Lost to follow-up | 7 | 4 |
| Withdrew: Withdrawal by subject | 10 | 15 |
| Withdrew: Other | 3 | 0 |
Inadequate glycaemic control and need for treatment intensification was defined as a glycosylated haemoglobin (HbA1c) of 7.0% or greater at 2 consecutive visits from week 26, including week 26 if HbA1c was greater than or equal to 7% at week 12. Time from randomisation to inadequate glycaemic control and need for treatment intensification was analysed using a stratified log-rank test where treatment, baseline HbA1c group and previous OAD treatment were included as strata in the model. The variable "baseline HbA1c group" was a dichotomised baseline HbA1c variable with 2 categories: HbA1c \< 8.5% or HbA1c ≥ 8.5% and the variable "previous OAD treatment" was a categorical variable with 2 categories: SU ± OAD(s) (SU users) or OAD(s) (Non-SU users). 25%, median (50%) and 75% percentiles for the cumulative distribution function were obtained from the Kaplan-Meier survival function.
| Weeks | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Baseline HbA1c <8.5% + Non-SU users | NA (104.0 to NA) | 104.3 (38.1 to NA) |
| Baseline HbA1c <8.5% + SU users | 106.7 (89.9 to NA) | 90.3 (26.4 to 105.1) |
| Baseline HbA1c >=8.5% + Non-SU users | NA (39.7 to NA) | 64.6 (26.1 to 105.1) |
| Baseline HbA1c >=8.5% + SU users | 104.0 (26.4 to NA) | 26.6 (26.1 to 91.1) |
Time to HbA1c \> 6.5% at 2 consecutive visits is defined as time from randomization to HbA1c \> 6.5% at 2 consecutive planned scheduled visits from week 26 (including week 26 if HbA1c was \> 6.5% at week 12). Time from randomisation to HbA1c \>6.5% at 2 consecutive visits was analysed using a stratified log-rank test where treatment, baseline HbA1c group and previous OAD treatment were included as strata in the model. The variable "baseline HbA1c group" was a dichotomised baseline HbA1c variable with 2 categories: HbA1c \< 8.5% or HbA1c ≥ 8.5% and the variable "previous OAD treatment" was a categorical variable with 2 categories: SU ± OAD(s) (SU users) or OAD(s) (Non-SU users). 25%, median (50%) and 75% percentiles for the cumulative distribution function were obtained from the Kaplan-Meier survival function.
| Weeks | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Baseline HbA1c <8.5% + Non-SU users | NA (52.1 to NA) | 64.1 (26.1 to 104.3) |
| Baseline HbA1c <8.5% + SU users | 90.1 (27.0 to NA) | 26.6 (26.1 to 89.9) |
| Baseline HbA1c >=8.5% + Non-SU users | 64.1 (26.1 to NA) | 26.6 (26.1 to 90.1) |
| Baseline HbA1c >=8.5% + SU users | 52.1 (26.1 to 104.1) | 26.1 (26.1 to 38.1) |
Change in HbA1c from baseline (week 0) to week 26 is presented.
| Percentage of HbA1c | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Change in HbA1c | -1.99 ± 1.14 | -1.69 ± 1.10 |
Change in body weight from baseline (week 0) to week 26 and week 104 is presented.
| Kilogram (kg) | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 0.5 ± 3.3 | 2.2 ± 3.6 |
| Week 104 | 1.2 ± 4.9 | 3.0 ± 4.9 |
Insulin dose after 26 and 104 weeks of treatment is presented.
| Units | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 34.6 ± 13.4 | 48.6 ± 28.2 |
| Week 104 | 36.1 ± 12.9 | 50.6 ± 31.5 |
Percentage of participants who achieved (yes/no) HbA1c \<7.0% at week 26 and week 104 is presented.
| Percentage of participants | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: Yes | 78.7 | 55.7 |
| Week 26: No | 21.3 | 44.3 |
| Week 104: Yes | 55.5 | 28.5 |
| Week 104: No | 44.5 | 71.5 |
Percentage of participants who achieved (yes/no) HbA1c \<7.0% without weight gain at week 26 and week 104 is presented.
| Percentage of participants | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: Yes | 38.5 | 15.4 |
| Week 26: No | 61.5 | 84.6 |
| Week 104: Yes | 20.9 | 6.3 |
| Week 104: No | 79.1 | 93.7 |
Severe or BG confirmed symptomatic hypoglycaemia was defined as an episode that was severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Percentage of participants who achieved (yes/no) HbA1c \<7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes at week 26 and week 104 is presented.
| Percentage of participants | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: Yes | 71.3 | 44.9 |
| Week 26: No | 28.7 | 55.1 |
| Week 104: Yes | 51.8 | 25.5 |
| Week 104: No | 48.2 | 74.5 |
Severe or BG confirmed symptomatic hypoglycaemia was defined as an episode that was severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Percentage of participants who achieved (yes/no) HbA1c \<7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes and without weight gain at week 26 and week 104 is presented.
| Percentage of participants | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: Yes | 35.2 | 13.6 |
| Week 26: No | 64.8 | 86.4 |
| Week 104: Yes | 20.0 | 6.1 |
| Week 104: No | 80.0 | 93.9 |
Percentage of participants who achieved (yes/no) HbA1c ≤6.5% at week 26 and week 104 is presented.
| Percentage of participants | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: Yes | 63.6 | 35.4 |
| Week 26: No | 36.4 | 64.6 |
| Week 104: Yes | 43.3 | 21.7 |
| Week 104: No | 56.7 | 78.3 |
Percentage of participants who achieved (yes/no) HbA1c ≤6.5% without weight gain at week 26 and week 104 is presented.
| Percentage of participants | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: Yes | 33.2 | 9.9 |
| Week 26: No | 66.8 | 90.1 |
| Week 104: Yes | 17.6 | 5.7 |
| Week 104: No | 82.4 | 94.3 |
Severe or BG confirmed symptomatic hypoglycaemia is defined as an episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Percentage of participants who achieved (yes/no) HbA1c ≤6.5% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes at week 26 and week 104 is presented.
| Percentage of participants | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: Yes | 57.9 | 27.9 |
| Week 26: No | 42.1 | 72.1 |
| Week 104: Yes | 40.1 | 19.2 |
| Week 104: No | 59.9 | 80.8 |
Severe or BG confirmed symptomatic hypoglycaemia is defined as an episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Percentage of participants who achieved (yes/no) HbA1c ≤6.5% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes and without weight gain at week 26 and week 104 is presented.
| Percentage of participants | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: Yes | 30.2 | 8.7 |
| Week 26: No | 69.8 | 91.3 |
| Week 104: Yes | 16.6 | 5.5 |
| Week 104: No | 83.4 | 94.5 |
Change in fasting plasma glucose (FPG) from baseline (week 0) to week 26 and week 104 is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | -3.97 ± 3.06 | -3.79 ± 3.18 |
| Week 104 | -3.93 ± 2.96 | -3.73 ± 2.75 |
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. Self-measured plasma glucose (SMPG)-9-point profile (individual points in the profile) at week 26 and week 104 is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: Before breakfast | 5.59 ± 1.57 | 5.58 ± 1.58 |
| Week 26: 90 minutes after breakfast | 8.34 ± 2.62 | 8.76 ± 2.68 |
| Week 26: Before lunch | 6.03 ± 2.00 | 6.43 ± 2.24 |
| Week 26: 90 minutes after lunch | 8.02 ± 2.32 | 8.79 ± 2.64 |
| Week 26: Before dinner | 6.67 ± 2.26 | 6.91 ± 2.35 |
| Week 26: 90 minutes after dinner | 8.31 ± 2.47 | 9.10 ± 2.70 |
| Week 26: Bedtime | 7.48 ± 2.42 | 8.13 ± 2.68 |
| Week 26: At 4:00 a.m. | 5.72 ± 1.55 | 5.91 ± 1.99 |
| Week 26: Before breakfast the following day | 5.53 ± 1.37 | 5.56 ± 1.56 |
| Week 104: Before breakfast | 5.58 ± 1.38 | 5.57 ± 1.27 |
| Week 104: 90 minutes after breakfast | 7.99 ± 2.50 | 8.64 ± 2.59 |
| Week 104: Before lunch | 6.06 ± 1.91 | 6.37 ± 2.02 |
| Week 104: 90 minutes after lunch | 7.80 ± 2.16 | 8.87 ± 2.45 |
| Week 104: Before dinner | 6.58 ± 1.97 | 7.02 ± 2.45 |
| Week 104: 90 minutes after dinner | 8.20 ± 2.20 | 9.10 ± 2.61 |
| Week 104: Bedtime | 7.47 ± 2.17 | 7.90 ± 2.41 |
| Week 104: At 4:00 a.m. | 5.67 ± 1.35 | 5.96 ± 1.73 |
| Week 104: Before breakfast the following day | 5.44 ± 1.23 | 5.47 ± 1.35 |
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. Change in SMPG-mean 9-point profile from baseline (week 0) to week 26 and week 104 is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | -3.34 ± 2.46 | -3.32 ± 2.62 |
| Week 104 | -3.27 ± 2.36 | -2.76 ± 2.41 |
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. Change in SMPG-mean postprandial increment over all meals from baseline (week 0) to week 26 and week 104 is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | -0.28 ± 2.13 | 0.20 ± 2.17 |
| Week 104 | -0.47 ± 1.99 | 0.12 ± 2.17 |
Change in blood pressure (systolic and diastolic) from baseline (week 0) to week 26 and week 104 is presented.
| Millimeters of mercury (mmHg) | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: Systolic blood pressure | -1.2 ± 14.0 | 0.5 ± 13.1 |
| Week 26: Diastolic blood pressure | 0.1 ± 8.8 | -0.3 ± 8.4 |
| Week 104: Systolic blood pressure | 0.5 ± 14.3 | 0.9 ± 13.6 |
| Week 104: Diastolic blood pressure | -0.1 ± 8.8 | -0.2 ± 8.6 |
Change in fasting C-peptide (measured in nanomoles per liter \[nmol/L\]) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
| Ratio of C-peptide | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 0.63 ± 60.79 | 0.57 ± 62.44 |
| Week 104 | 0.58 ± 64.21 | 0.54 ± 70.45 |
Change in fasting human insulin (measured in picomoles per liter \[pmol/L\]) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
| Ratio of insulin | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 0.67 ± 90.68 | 0.68 ± 89.19 |
| Week 104 | 0.60 ± 91.84 | 0.62 ± 92.55 |
Change in fasting total cholesterol (measured in mmol/L) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
| Ratio of total cholesterol | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 0.99 ± 17.38 | 0.99 ± 17.68 |
| Week 104 | 0.97 ± 19.11 | 0.97 ± 20.40 |
Change in fasting low density lipoprotein (LDL)-cholesterol (measured in mmol/L) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
| Ratio of LDL-cholesterol | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 1.05 ± 35.97 | 1.02 ± 30.10 |
| Week 104 | 0.96 ± 38.83 | 0.98 ± 34.40 |
Change in fasting high density lipoprotein (HDL)- cholesterol (measured in mmol/L) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
| Ratio of HDL-cholesterol | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 1.03 ± 16.61 | 1.02 ± 15.57 |
| Week 104 | 1.02 ± 16.93 | 1.03 ± 17.36 |
Change in fasting very low density lipoprotein (VLDL)-cholesterol (measured in mmol/L) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
| Ratio of VLDL-cholesterol | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 0.85 ± 40.78 | 0.85 ± 42.01 |
| Week 104 | 0.90 ± 40.90 | 0.88 ± 35.98 |
Change in fasting triglycerides (measured as mmol/L) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
| Ratio of triglycerides | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 0.84 ± 43.82 | 0.85 ± 45.75 |
| Week 104 | 0.89 ± 42.20 | 0.89 ± 40.08 |
Change in fasting free fatty acids (measured as mmol/L) from baseline (week 0) to week 26 and week 104 is presented as ratio to baseline.
| Ratio of free fatty acids | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 0.68 ± 59.69 | 0.75 ± 60.25 |
| Week 104 | 0.70 ± 57.71 | 0.78 ± 59.48 |
Severe or BG confirmed symptomatic hypoglycaemia is defined as an episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during 26 weeks of treatment is presented.
| Episodes | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks of Treatment | 143 | 261 |
Severe or BG confirmed symptomatic hypoglycaemia is defined as an episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during 104 weeks of treatment is presented.
| Episodes | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 104 Weeks of Treatment | 319 | 642 |
Hypoglycaemic episodes (SMPG value ≤3.9 mmol/L (70 mg/dL)) were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent hypoglycaemic episodes according to ADA during 26 weeks of treatment is presented.
| Episodes | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Number of Treatment Emergent Hypoglycaemic Episodes During 26 Weeks of Treatment | 3190 | 3806 |
Hypoglycaemic episodes (SMPG value ≤3.9 mmol/L (70 mg/dL)) were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment emergent hypoglycaemic episodes according to ADA during 104 weeks of treatment is presented.
| Episodes | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Number of Treatment Emergent Hypoglycaemic Episodes During 104 Weeks of Treatment | 8934 | 10658 |
Severe or BG confirmed symptomatic hypoglycaemia is defined as an episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 both inclusive. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes during 26 weeks of treatment is presented.
| Episodes | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks of Treatment | 27 | 60 |
Severe or BG confirmed symptomatic hypoglycaemia is defined as an episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 both inclusive. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes during 104 weeks of treatment is presented.
| Episodes | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 104 Weeks of Treatment | 61 | 164 |
An adverse event is any untoward medical occurrence in a participant administered a product, and which does not necessarily have a causal relationship with this treatment. A treatment emergent adverse event (TEAE) was defined as an adverse event that had onset date on or after the first day of exposure to trial product and no later than 7 days after the last day of trial product. If the event had onset date before the first day of exposure on trial product and increased in severity during the treatment period and until 7 days after the last drug date, then this event was also considered as a TEAE. Number of TEAEs during 26 weeks of treatment is presented.
| Adverse events | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Number of TEAEs During 26 Weeks of Treatment | 718 | 624 |
An adverse event is any untoward medical occurrence in a participant administered a product, and which does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event that had onset date on or after the first day of exposure to trial product and no later than 7 days after the last day of trial product. If the event had onset date before the first day of exposure on trial product and increased in severity during the treatment period and until 7 days after the last drug date, then this event was also considered as a TEAE. Number of TEAEs during 104 weeks of treatment is presented.
| Adverse events | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Number of TEAEs During 104 Weeks of Treatment | 1788 | 1368 |
Fundus photography or a dilated fundoscopy was performed at baseline (within 12 weeks prior to week 0) and week 104. The investigator interpreted each eye's (left and right) results and categorised them as: normal, abnormal not clinically significant (NCS) or abnormal clinically significant (CS). Number of participants in each category at baseline and week 104 were presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Left eye: Normal (baseline) | 345 | 341 |
| Left eye: Abnormal NCS (baseline) | 151 | 155 |
| Left eye: Abnormal CS (baseline) | 10 | 8 |
| Left eye: Normal (week 104) | 204 | 129 |
| Left eye: Abnormal NCS (week 104) | 97 | 50 |
| Left eye: Abnormal CS (week 104) | 17 | 6 |
| Right eye: Normal (baseline) | 344 | 355 |
| Right eye: Abnormal NCS (baseline) | 151 | 143 |
| Right eye: Abnormal CS (baseline) | 11 | 6 |
| Right eye: Normal (week 104) | 200 | 132 |
| Right eye: Abnormal NCS (week 104) | 99 | 48 |
| Right eye: Abnormal CS (week 104) | 19 | 5 |
The electrocardiogram (ECG) was assessed at baseline (within 2 weeks prior to week 0) and week 104. The investigator interpreted the results and categorised them as: normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 104 are presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Normal (Baseline) | 335 | 335 |
| Abnormal NCS (Baseline) | 162 | 165 |
| Abnormal CS (Baseline) | 9 | 4 |
| Normal (week 104) | 227 | 122 |
| Abnormal NCS (week 104) | 97 | 65 |
| Abnormal CS (week 104) | 7 | 2 |
Change in urine albumin/creatinine ratio from baseline (week 0) to week 104 is presented.
| Milligrams per millimole (mg/mmol) | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Change in Urine Albumin/Creatinine Ratio | -1.09 ± 7.43 | -0.74 ± 15.58 |
Change in pulse rate from baseline (week 0) to week 26 and week 104 is presented.
| Beats per minute | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 2.0 ± 8.8 | -0.4 ± 8.7 |
| Week 104 | 1.7 ± 9.3 | -0.5 ± 9.7 |
Change in biochemistry parameter- creatinine, total bilirubin from baseline (week 0) to week 26 and week 104 is presented.
| Micromoles per liter (umol/L) | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: creatinine | -0.50 ± 10.08 | 0.25 ± 8.78 |
| Week 104: creatinine | 0.75 ± 10.85 | 2.20 ± 11.86 |
| Week 26: total bilirubin | -0.30 ± 3.35 | -0.32 ± 2.80 |
| Week 104: total bilirubin | -0.33 ± 3.42 | -0.59 ± 3.01 |
Change in biochemistry parameter- albumin from baseline (week 0) to week 26 and week 104 is presented.
| Grams per deciliter (g/dL) | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | -0.03 ± 0.24 | -0.03 ± 0.21 |
| Week 104 | 0.01 ± 0.24 | 0.03 ± 0.27 |
Change in biochemistry parameters- alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lipase and amylase from baseline (week 0) to week 26 and week 104 is presented.
| Units per liter (U/L) | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: ALP | -4.16 ± 14.16 | -4.33 ± 12.84 |
| Week 104: ALP | -1.35 ± 15.71 | -1.34 ± 14.22 |
| Week 26: ALT | -5.45 ± 18.50 | -3.33 ± 13.24 |
| Week 104: ALT | -5.39 ± 14.16 | -3.45 ± 14.46 |
| Week 26: AST | -1.62 ± 9.78 | -0.39 ± 9.51 |
| Week 104: AST | -1.84 ± 9.86 | -0.67 ± 10.78 |
| Week 26: lipase | 9.26 ± 42.92 | -7.97 ± 34.28 |
| Week 104: lipase | 5.41 ± 48.35 | -13.33 ± 42.27 |
| Week 26: amylase | 9.72 ± 23.28 | 2.79 ± 20.92 |
| Week 104: amylase | 7.23 ± 25.42 | -0.13 ± 25.94 |
Change in sodium, potassium and calcium from baseline (week 0) to week 26 and week 104 is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: sodium | 0.89 ± 2.74 | 1.03 ± 2.61 |
| Week 104: sodium | 1.22 ± 2.54 | 1.47 ± 2.39 |
| Week 26: potassium | -0.05 ± 0.40 | -0.08 ± 0.42 |
| Week 104: potassium | -0.06 ± 0.42 | -0.07 ± 0.43 |
| Week 26: calcium | -0.01 ± 0.11 | -0.00 ± 0.11 |
| Week 104: calcium | -0.07 ± 0.10 | -0.06 ± 0.11 |
Change in haemoglobin from baseline (week 0) to week 26 and week 104 is presented.
| g/dL | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 0.08 ± 0.72 | 0.08 ± 0.74 |
| Week 104 | -0.00 ± 0.89 | -0.03 ± 0.92 |
Change in haematocrit from baseline (week 0) to week 26 and week 104 is presented.
| Percentage of red blood cells | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | -0.33 ± 2.45 | -0.36 ± 2.43 |
| Week 104 | -0.71 ± 2.83 | -0.95 ± 3.02 |
Change in erythrocytes from baseline (week 0) to week 26 and week 104 is presented.
| 10^12 cells/L | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | -0.02 ± 0.28 | -0.03 ± 0.27 |
| Week 104 | -0.12 ± 0.30 | -0.11 ± 0.32 |
Change in thrombocytes and leukocytes from baseline (week 0) to week 26 and week 104 is presented.
| 10^9 cells/L | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: Thrombocytes | 8.77 ± 35.82 | 7.05 ± 41.71 |
| Week 104: Thrombocytes | 16.87 ± 39.27 | 18.73 ± 53.76 |
| Week 26: Leukocytes | 0.49 ± 1.45 | 0.39 ± 1.43 |
| Week 104: Leukocytes | 0.07 ± 1.50 | 0.32 ± 1.55 |
Change in eosinophils from baseline (week 0) to week 26 and week 104 is presented.
| Percentage of eosinophils | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 0.10 ± 1.88 | 0.06 ± 2.09 |
| Week 104 | 0.32 ± 2.08 | 0.43 ± 1.56 |
Change in neutrophils from baseline (week 0) to week 26 and week 104 is presented.
| Percentage of neutrophils | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 1.86 ± 7.20 | 0.78 ± 7.68 |
| Week 104 | 1.25 ± 7.94 | 1.21 ± 8.02 |
Change in basophils from baseline (week 0) to week 26 and week 104 is presented.
| Percentage of basophils | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 0.00 ± 0.28 | -0.00 ± 0.29 |
| Week 104 | 0.20 ± 0.38 | 0.16 ± 0.35 |
Change in monocytes from baseline (week 0) to week 26 and week 104 is presented.
| Percentage of monocytes | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | -0.10 ± 2.04 | 0.01 ± 1.91 |
| Week 104 | 0.49 ± 2.02 | 0.59 ± 1.88 |
Change in lymphocytes from baseline (week 0) to week 26 and week 104 is presented.
| Percentage of lymphocytes | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | -1.87 ± 6.29 | -0.84 ± 6.73 |
| Week 104 | -2.25 ± 6.76 | -2.38 ± 7.29 |
The number of participants who reported low, normal and high levels of calcitonin in relation to reference ranges at baseline (week 0), week 26 and week 104 are presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 0: Low | 0 | 0 |
| Week 0: Normal | 481 | 472 |
| Week 0: High | 25 | 32 |
| Week 26: Low | 0 | 0 |
| Week 26: Normal | 437 | 431 |
| Week 26: High | 40 | 30 |
| Week 104: Low | 0 | 0 |
| Week 104: Normal | 301 | 169 |
| Week 104: High | 31 | 17 |
SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ (acute version) questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary (PCS) and mental component summary (MCS)). The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in the sub-domain scores and component summary (PCS and MCS) scores are presented. A positive change score indicates an improvement since baseline.
| Score on a scale | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26: Physical functioning | 1.2 ± 6.8 | 1.1 ± 7.0 |
| Week 104: Physical functioning | 0.7 ± 7.5 | 0.6 ± 7.9 |
| Week 26: Role-physical | 1.4 ± 7.7 | 0.5 ± 7.4 |
| Week 104: Role-physical | 1.4 ± 8.7 | 0.7 ± 7.5 |
| Week 26: Bodily pain | 1.5 ± 9.7 | 0.4 ± 10.0 |
| Week 104: Bodily pain | 1.6 ± 11.2 | 0.1 ± 8.5 |
| Week 26: General health | 2.5 ± 8.2 | 2.1 ± 7.6 |
| Week 104: General health | 2.3 ± 8.7 | 2.1 ± 8.3 |
| Week 26: Vitality | 1.4 ± 8.1 | 1.4 ± 8.0 |
| Week 104: Vitality | 1.5 ± 8.4 | 1.5 ± 8.0 |
| Week 26: Social functioning | 1.8 ± 8.1 | 0.9 ± 8.8 |
| Week 104: Social functioning | 0.9 ± 8.9 | 1.1 ± 7.6 |
| Week 26: Role-emotional | 0.6 ± 8.9 | 0.7 ± 8.8 |
| Week 104: Role-emotional | 1.6 ± 10.1 | 1.2 ± 8.2 |
| Week 26: Mental health | 1.7 ± 8.7 | 1.3 ± 8.4 |
| Week 104: Mental health | 2.5 ± 9.4 | 0.3 ± 8.9 |
| Week 26: PCS | 1.6 ± 6.3 | 0.9 ± 6.3 |
| Week 104: PCS | 1.0 ± 7.2 | 0.8 ± 6.0 |
| Week 26: MCS | 1.3 ± 8.2 | 1.2 ± 8.0 |
| Week 104: MCS | 2.0 ± 9.0 | 1.0 ± 7.8 |
Treatment related impact measures-diabetes (TRIM-D) was developed according to the FDA guidance from 2009 on development of new PRO measures. The questionnaire consists of 5 sub-domains, which are scored according to a 1-5 point scale with a higher score indicating a better health state (less negative impact). Sub-domain scores are calculated by summing across items in the same sub-domain, and the total score is calculated by summing scores from all the sub-domains. The highest possible summed score within a sub-domain ranges from 20 (compliance sub-domain) to 40 (psychological health sub-domain) points and the highest possible total score is 140 points. Change in TRIM-D total score from baseline (week 0) to week 26 and week 104 is presented. A positive change score indicates an improvement since baseline.
| Score on a scale | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Week 26 | 9.6 ± 12.4 | 7.3 ± 13.1 |
| Week 104 | 11.4 ± 13.7 | 9.5 ± 12.8 |
Collected over Weeks 0-104 (treatment period) + 7 days follow-up-1 + 30 days follow-up-2. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Degludec/Liraglutide | 2/506 (0.4%) | 60/506 (11.9%) | 206/506 (40.7%) |
| Insulin Glargine | 5/504 (1%) | 43/504 (8.5%) | 156/504 (31%) |
| Event | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| Angina unstableCardiac disorders | 4/506 | 0/504 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 4/506 | 3/504 |
| CholelithiasisHepatobiliary disorders | 2/506 | 3/504 |
| Acute myocardial infarctionCardiac disorders | 3/506 | 2/504 |
| Cholecystitis acuteHepatobiliary disorders | 3/506 | 1/504 |
| FallInjury, poisoning and procedural complications | 3/506 | 0/504 |
| Lower respiratory tract infectionInfections and infestations | 3/506 | 0/504 |
| Peripheral arterial occlusive diseaseVascular disorders | 3/506 | 0/504 |
| Atrial fibrillationCardiac disorders | 0/506 | 2/504 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/506 | 2/504 |
| Event | Insulin Degludec/Liraglutide | Insulin Glargine |
|---|---|---|
| HeadacheNervous system disorders | 58/506 | 45/504 |
| NasopharyngitisInfections and infestations | 57/506 | 44/504 |
| DiarrhoeaGastrointestinal disorders | 39/506 | 12/504 |
| Upper respiratory tract infectionInfections and infestations | 28/506 | 36/504 |
| InfluenzaInfections and infestations | 36/506 | 28/504 |
| NauseaGastrointestinal disorders | 31/506 | 8/504 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 24/506 | 29/504 |
| Back painMusculoskeletal and connective tissue disorders | 25/506 | 27/504 |
Full analysis set (FAS) included all randomised participants.
| Age, Continuous(Years) | Insulin Degludec/Liraglutide | Insulin Glargine | Total |
|---|---|---|---|
| Mean | 56.8 ± 10.0 | 56.4 ± 10.1 | 56.6 ± 10.0 |
| Sex: Female, Male(Participants) | Insulin Degludec/Liraglutide | Insulin Glargine | Total |
|---|---|---|---|
| Female | 226 | 231 | 457 |
| Male | 280 | 275 | 555 |
| Ethnicity (NIH/OMB)(Participants) | Insulin Degludec/Liraglutide | Insulin Glargine | Total |
|---|---|---|---|
| Hispanic or Latino | 115 | 126 | 241 |
| Not Hispanic or Latino | 391 | 380 | 771 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Insulin Degludec/Liraglutide | Insulin Glargine | Total |
|---|---|---|---|
| White | 424 | 414 | 838 |
| Black or African American | 25 | 28 | 53 |
| Asian | 54 | 61 | 115 |
| Other | 3 | 3 | 6 |
Showing the first 100 of 143 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2016 to primary completion in Oct 2018, 32 months.
Results were first posted in Nov 2019, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 32 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Liraglutide